Publication Brief

As the Alzheimer’s disease (AD) research community accelerates efforts toward earlier diagnosis and more targeted therapeutic interventions, tau phosphorylation biomarkers have taken center stage for their potential to precisely map disease progression. Among these, site-specific phosphorylated tau species are now understood to represent distinct stages of tau pathobiology, from early seeding and conformational changes to mature neurofibrillary tangle accumulation. Recognizing this continuum, Quanterix has developed and launched two new ultrasensitive Simoa^® assays: p-Tau 205 and p-Tau 212, which add critical granularity to the phosphorylated tau biomarker landscape.

Download our publication brief to learn more and to view a sampling of peer-reviewed research using Simoa® technology.